What We're Reading: Page 35
Industry reads hand-picked by our editors
Nov 06, 2024
-
The Washington Post
RFK Jr. eyes a major food, health role in potential Trump administration
-
Axios
Massachusetts voters reject psychedelics
-
Reuters
Novo Nordisk is aware of 10 deaths from compounded weight-loss drug copies
-
Nature News
The antibodies don’t work! The race to rid labs of molecules that ruin experiments
Nov 05, 2024
-
Crain’s Chicago Business
Tempus buying genetics lab company for $600 million
-
Reuters
Catalent misses Q1 revenue estimates ahead of deal close with Novo Holdings
-
Fierce Biotech
FDA delays decision on Merus’ first-in-class cancer drug
Nov 04, 2024
-
Reuters
EU antitrust regulators to rule on Novo’s Catalent buy by Dec. 6
-
FirstWord Pharma
FDA raises alarm over certain compounded GLP-1s due to sterility concerns
-
MIT Technology Review
How CRISPR will help the world cope with climate change
Nov 01, 2024
-
Science
Can people be ‘inoculated’ against misinformation?
-
The Wall Street Journal
U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners
-
Agency IQ
Trump may hand control of FDA over to RFK Jr. Here’s what that could mean for FDA and industry
-
Reuters
How Asian pharma suppliers cash in on Ozempic copies
Oct 31, 2024
Oct 30, 2024
-
Reuters
Gradual dosing of Lilly Alzheimer’s drug cuts brain-swelling risk, study finds
-
Fierce Pharma
Novartis’ Scemblix leaps into newly diagnosed leukemia—where winning over doctors may take time
-
CNN
What alarms health experts most about RFK Jr. is what he’s leaving out of his health policy proposals
Previous
